• About us
• Contact

Advertisement

Organisation › Details

Adcendo ApS

Adcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug conjugates (ADCs) for treatment of cancers. It was founded in 2017 by scientists Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen, and Henrik Stage, a biotech-entrepreneur active in several biotech companies, and previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014. In 2018, Adcendo was awarded a pre-seed grant from the Novo Nordisk Foundation, the owner of Novo Holdings, to help the company develop the commercial potential of its research discovery. The scientific advisory board includes John Lambert PhD, the former CSO of ImmunoGen, Vincent de Groot PhD, Founder of the ADC company Syntarga, and Murray Yule MD, PhD, Oncologist experienced in translational oncology including ADCs. *

 

	Start	2017-01-01 established (s-off)
	Predecessor	University of Copenhagen
	Industry	antibody-drug conjugate (ADC)
	Industry 2	oncology
	Person	Pehl, Michael (Adcendo 202107– CEO before Gemoab + Immunomedics + Celgene + Amgen)
	Person 2	Stage, Henrik (Adcendo 202107– CFO before CEO formerly Santaris Pharma 201401 CFO)
	Region	København (Copenhagen)
	Country	Denmark
	Street	3 Ole Maaløes Vej BioInnovation Institute (BII)
	City	2200 København
		Address record changed: 2020-12-02
Basic data	Employees	A: 1 to 10 (2019-12-24)
		* Document for »About Section«: Adcendo ApS. (4/29/21). "Press Release: Adcendo Raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers". Copenhagen.
		Record changed: 2024-08-22

Advertisement

More documents for Adcendo ApS

• [1] Adcendo ApS. (8/20/24). "Press Release: Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor". Copenhagen & Shanghai....
• [2] Adcendo ApS. (5/29/24). "Press Release: Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline". Copenhagen....
• [3] Adcendo ApS. (5/30/23). "Press Release: Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline". Copenhagen....
• [4] Adcendo ApS. (4/4/23). "Press Release: Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline". Copenhagen....
• [5] Adcendo ApS. (1/5/23). "Press Release: Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform". Copenhagen....
• [6] Adcendo ApS. (12/19/22). "Press Release: GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate"....
• [7] Adcendo ApS. (7/6/21). "Press Release: Adcendo Appoints Michael Pehl as Chief Executive Officer"....
• [8] Adcendo ApS. (4/29/21). "Press Release: Adcendo Raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.